Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma [0.03%]
靶向T细胞衔接剂在多发性骨髓瘤中相关感染的特征及预后意义
Lindsay Fogel,Harsh Parmar,Shucen Wan et al.
Lindsay Fogel et al.
Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group [0.03%]
Venetoclax联合利妥昔单抗治疗复发/难治慢性淋巴细胞白血病的疗效和耐受性——波兰成人急性白血病研究组真实世界分析
Anita Soboń,Elżbieta Iskierka-Jażdżewska,Joanna Drozd-Sokolowska et al.
Anita Soboń et al.
We collected clinical data on 363 patients with relapsed/refractory chronic lymphocytic leukemia (RR-CLL) treated with venetoclax-rituximab (VR) in a real-world setting. The median age was 69.5 years (range, 32.5-91.6 years), and the median...
Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study [0.03%]
慢性淋巴细胞白血病基线肝脏酶谱的预后意义：一项全国真实世界队列研究
Yotam Bronstein,Lior Rokach,Yair Herishanu et al.
Yotam Bronstein et al.
Liver biochemical abnormalities are relatively common at chronic lymphocytic leukemia (CLL) diagnosis, but their prognostic significance is unclear. We conducted a nationwide real-world study of 3448 adults with newly diagnosed CLL in Clali...
A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation [0.03%]
低剂量美法仑、硫鸟嘌呤和氟达拉滨作为非亲缘供者移植预处理方案的II期研究
Nikki Agarwal,Brenda W Cooper,Ben K Tomlinson et al.
Nikki Agarwal et al.
We conducted a phase II study of fludarabine, thiotepa, reduced dose melphalan conditioning for allogeneic transplantation using alternate donors. Thirty-eight patients with hematological malignancies were enrolled. Conditioning included fl...
Fatal differentiation syndrome-associated myocarditis caused by PML: RARα-positive neutrophils in acute promyelocytic leukemia [0.03%]
PML-RARα阳性早幼粒细胞白血病所致致死性分化综合征相关心肌炎伴有中性粒细胞增多症
Somi Ozaki,Kotaro Miyao,Sohei Yamamoto et al.
Somi Ozaki et al.
Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare [0.03%]
基于SEER-Medicare数据库的老年多发性骨髓瘤患者合并症模式及生存结局的研究
Atinuke G Oyinbo,Maira A Castaneda-Avila,Jonggyu Baek et al.
Atinuke G Oyinbo et al.
This study examined the association between multimorbidity patterns and survival in patients with multiple myeloma (2007-2017) using SEER-Medicare (n = 7281). We determined survival differences between patients with low severity multimorbid...
Efficacy of imatinib maintenance after stem cell transplantation for Ph+/ BCR:: ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease [0.03%]
伊马替尼巩固移植后治疗费城染色体阳性急性淋巴细胞白血病的疗效：一项随机研究的长期结局及其移植前后的微小残留病的影响
Heike Pfeifer,Wolfgang Bethge,Stefan Schönland et al.
Heike Pfeifer et al.
Tyrosine kinase inhibitors are recommended as maintenance therapy following allogeneic stem cell transplantation (HSCT) for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), but optimal medication, dose, and duratio...
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study [0.03%]
维奈克拉和低甲基化药物与其它疗法的比较：一项国际多中心回顾队列研究
Jacqueline S Garcia,Pinkal Desai,Joshua F Zeidner et al.
Jacqueline S Garcia et al.
Venetoclax (VEN) plus hypomethylating agents (HMA) is approved for newly diagnosed (ND) acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy (IC). This international retrospective chart review involving 17 academic...
Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort [0.03%]
针对复发或难治性多发性骨髓瘤的双特异性抗体和CAR-T细胞治疗的真实世界分析：一项全球TriNetX发现队列和当代验证队列的研究
Theo Leitner,Lorenz Oelschläger,Francisco Henriquez Mosquera et al.
Theo Leitner et al.
Bispecific antibodies (BsAbs) and BCMA-directed CAR-T cell therapies have transformed late-line relapsed/refractory multiple myeloma (RRMM), yet real-world comparisons are confounded by treatment selection, line of therapy, and supportive c...
Transfusion-Independent iron overload in SF3B1-mutant myelodysplastic syndrome case report [0.03%]
SF3B1突变型骨髓增生异常综合征相关输血独立性铁过载病例报告
Ashik Zala,Simone Claudiani,Simona Deplano
Ashik Zala